Podcasts about Cart

Don't have time to listen to the entire Dave & Chuck the Freak podcast? Check out some of the tastiest bits of the day, including chuck's new album songs of Cart-Man, a fart forces people to leave the new Spiderman movie and so much more!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression. Key topics included: The current treatment algorithms for late relapse refractory multiple myeloma The significance of antigen expression in guiding treatment decisions The role of bispecific antibodies like teclistamab and talquetamab Managing side effects and improving patient quality of life The importance of collaboration between community hematologists and tertiary care centers Join us as we explored the latest advancements in myeloma treatment and the critical role of patient education and support in navigating this challenging disease. Don't forget to check out our previous episodes on newly diagnosed multiple myeloma and early relapse refractory disease!   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Subscribe for more insights and updates on oncology treatments! #MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers

On this week's episode, Graig Suvannavejh, Tim Opler, Yaron Werber, Paul Matteis, and Brian Skorney kicked off with a review of the market, noting pressure in the XBI despite a longer-term bounce-back from trough levels, though they see biotech fundamentals as largely intact. The group also discussed the trend of reverse mergers as an alternative to traditional IPOs, along with AI's expansion and uncertain role in accelerating drug discovery. In regulatory news, the co-hosts welcomed the return of FDA advisory committee meetings, including those for Capricor and Replimune, and highlighted Anthony Fauci's recent Senate testimony on the handling of the COVID-19 pandemic. In deals, J&J struck an in vivo CAR-T partnership with Sail Biomedicines, with potential readthroughs for Legend Biotech, and Argenx is set to acquire Forte Biosciences to bolster its immunology pipeline. The group also highlighted Lilly's recent acquisition of psychedelics company AtaiBeckley, opening a broader discussion on deals in the psychedelics space. The episode concluded with company news including Alnylam shares dropping 30% following disappointing updated guidance, Novo Nordisk's Phase 3 study for its anti-IL-6 ligand antibody, and MapLight's Phase 2 schizophrenia readout. *This episode aired on July 31, 2026.

El principal detonante de esta crisis es una sobreoferta estructural en el mercado global, impulsada mayoritariamente por la entrada de nueva capacidad de producción desde Asia.See omnystudio.com/listener for privacy information.

Cinco días antes de Navidad de 1984, Jonelle Matthews, de 12 años, desapareció de su casa en Greeley, Colorado. Su rostro fue de los primeros en aparecer en los cartones de leche, pero aquella difusión no consiguió traerla de vuelta.

>p>Broadcast from KSQD, Santa Cruz on 7-30-2026: A type of coffee brewed from beans that have been altered by passage through the digestive track of civet cats is a delicacy in Southeast Asia. A Scientific Reports paper using gas chromatography analyzed Kopi Luwak (civet-processed coffee beans) versus fresh-picked beans, finding elevated caprylic and capric acids that carry the characteristic flavor notes found in dairy products. Dr. Manuel Esteller sampled and tested the blood, saliva, urine, and stool of the oldest human Maria Branyas Morera, who died last year at 117. Despite exceptionally short telomeres, she carried anti-inflammatory genetic variants seen in long-lived dogs, worms, and flies, and had unusually high Bifidobacterium levels—likely boosted by her three-daily-servings-of-yogurt habit. Dr. Dawn defends sunscreen use against Environmental Working Group scare campaigns, noting that concerns about absorption of sunscreen ingredients into blood remain theoretical while sunburn's melanoma link is well-established. She argues that a badly sunburned toddler starts a clock that can produce melanoma by the late teens. The FDA advisory committee is reviewing certain short amino acid chains popularly known as "peptides" for potential compounding-pharmacy production, covering proposed to treat ulcerative colitis, wound healing, insomnia, insulin resistance, migraines, and osteoporosis. Dr. Dawn flags that five to seven committee members have industry conflicts of interest, but argues that even flawed approval is preferable to the current gray market, where analysis shows vials contain only 4-28% of labeled content along with endotoxin and toluene contamination. She proposes surveillance tracking of prescribed peptides to catch adverse effects early, citing a foreign melanocortin nasal spray tanning product that caused rare nasal melanomas as a cautionary example. Utah State biochemists working with the Cas12a2 CRISPR enzyme discovered that instead of behaving as a precise gene-editor like Cas9, it goes into an indiscriminate DNA-shredding mode after recognizing its target RNA. By programming it to recognize RNA sequences uniquely activated in cancer cells (embryonic-development genes that shouldn't be running in adults), researchers destroyed only the cancer cells in tissue culture, potentially offering a way to eliminate small metastases without healthy tissue toxicity. Cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitor therapy showed dramatically improved outcomes, with median survival in advanced lung cancer rising from 20 to 37 months. Non-mRNA vaccines (flu, pneumonia) showed no such benefit. Lab work suggests the mRNA triggers type-1 interferon release that activates tumor-infiltrating immune cells and drives them to lymph nodes to train other immune cells against the tumor. Researchers redesigned a CD40 agonist antibody to bind multiple receptors simultaneously by clustering with a second antibody, stretching the cell surface and triggering a powerful immune response. In a 12-patient trial, injecting one tumor caused all tumors to shrink in six patients and produced complete remission in two—including a melanoma patient with dozens of leg tumors and a metastatic breast cancer patient whose lung and liver tumors resolved after skin injection. Two small trials of CAR natural killer cells—engineered like CAR T-cells but derived from donor umbilical cord blood and thus potentially available off-the-shelf—showed remarkable results in autoimmune disease. All 27 systemic lupus patients targeting the CD19 protein on autoantibody-producing cells showed improvement, with some remaining in remission at nearly two years. A single Shanghai patient with systemic sclerosis showed restoration of normal skin and blood vessel structure. A paradox has emerged in advanced prostate cancer: while blocking testosterone halts early tumor growth, cancer cells eventually adapt to low-androgen conditions such that flooding tissues with testosterone in advanced disease can actually halt tumor progression by triggering cellular redifferentiation. Separately, Dr. Dawn reviews conflicting evidence on Parkinson's risk from androgen deprivation therapy, singling out enzalutamide (Xtandi) as the most concerning drug due to blood-brain barrier penetration, and recommending darolutamide as the safest alternative with matching prostate efficacy but minimal CNS entry.

Welcome back to Not A Bomb, the podcast where we resurrect cinema's most infamous box office disasters and ask the burning question: is it a bomb? This week, Troy and Brad strap into the chaotic, nitro‑fueled world of the 2001 racing epic Driven. And before we go any further, yes, Troy is back from surgery and only slightly a little high on pain medication, which honestly might be the perfect state of mind for revisiting a movie this unintentionally wild.Driven arrived during the era when Hollywood believed the cure for every script problem was “more CGI, more speed, more Stallone.” The film promised high‑octane racing, intense rivalries, and behind‑the‑scenes drama in the world of CART. What audiences got instead was a dizzying mix of digital car mayhem, melodramatic speeches, and physics‑defying crashes.Troy and Brad dig into the film's over‑the‑top action sequences, the baffling script choices, and one of the worst displays of “acting” this podcast has ever seen…. cough, cough - KIP! They also explore how the film's reputation has evolved, why some viewers have embraced its unintentional charm, and whether Driven deserves a second look or remains a cautionary tale about letting Stallone write his own sports movies.Buckle up, avoid the flying manhole covers, and prepare for a ride that makes absolutely no sense. This is one cinematic spinout worth revisiting.Want to help support the show? Head over to the Not A Bomb Tee Public store and check our merchandise. Special thanks to Ted Blair for the amazing designs!We're committed to hearing your feedback and suggestions. If there's a cinematic flop you'd like us to delve into, please reach out to us at NotABombPod@gmail.com or through our contact page. Your reviews and feedback are what drive us. If you enjoy our content, consider leaving a review on Apple Podcast or Spotify.Cast: Brad, Troy

Here's the Supporter-only Q&A from July 30th 2026. All comments and questions are fielded through the supporter service Q&A page.Please consider supporting this channel via monthly support services, tips, or even just by using our affiliate links to purchase things you were already going to buy anyway, at no extra cost to you:  https://www.retrorgb.com/support.htmlT-Shirts:  https://retrorgb.link/tshirtsAmazon Recommended List:  http://retrorgb.link/amazon TIMESTAMPS (please assume all links are affiliate / paid links that pay RetroRGB a commission on each sale.  Even if links are currently not affiliate, I may update them with one, should a partner list that item for sale in the future):00:00  Welcome!00:45  AES+ Output Info?:  https://retrorgb.com/new-official-neo-geo-aes.html 05:29  SMS to MK-2000 Converter:  https://retrorgb.com/sms.html08:42  RetroTINK plus Monitor BFI / Headphone Amp14:28  PVM + RetroTINK Setup, Dreamcast Video Issues20:11  SuperStation One Issues, VGA output, OLED Issues27:30  Cart setup for 12 consoles + CRT:  https://retrorgb.com/carts.html31:17  Genesis MiSTer Core Direct Video Issues32:52  Atari 7800 PSU34:14  Thank You:   https://www.retrorgb.com/support.html

As the marketing industry and the world at large continues to experience its own digital transformation, marketers have seen an explosion of channels, platforms, and of course data. To better understand the reality of today's marketing landscape and the tools at our disposal, we present our Tools of the Trade episode series. In this episode, we sit down with Mat Drela, retail media expert, author and path to purchase, 40 under 40 honoree at RMIQ, Red Door's exclusive retail media specialist partner. We cut through the hype to explain what retail media really is, why its closed loop measurement changes the game for challenger brands, and how the purchase data it generates can sharpen a brand's entire marketing plan. In this episode, we cover: What is retail media beyond Amazon? How does retail media close the loop? Why does retail media benefit challenger brands? Is ROAS enough to measure retail media success? How can retail media data shape brand strategy? Where do purchase signals add value? How should brands get started with retail media? Want to take the conversation further? Join us for our webinar, Click to Cart: How Retail Media Closes the Loop Between Ad & Sale, on Tuesday, August 25, at 10:00 a.m. PT.

ja entrou?http://orelo.cc/diariodebordo

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of events that underscore the dynamic nature of these industries, characterized by scientific advancements, strategic partnerships, and regulatory milestones. Johnson & Johnson has made headlines with its substantial $785 million upfront payment to Sail BioMed for an in vivo CAR-T cell therapy deal. This agreement includes an option for Johnson & Johnson to acquire Sail BioMed for $2.58 billion, underscoring the sustained interest in cell therapies, particularly for autoimmune diseases. In vivo CAR-T therapies represent a significant leap forward by modifying T cells directly within the patient's body. This method offers potential advantages over traditional ex vivo techniques by simplifying the manufacturing process and potentially reducing both costs and time to treatment. Such transactions highlight Johnson & Johnson's commitment to expanding its cell therapy portfolio, which could significantly enhance patient care by making advanced treatments more accessible. Eli Lilly and Resilience have announced a significant $750 million investment aimed at boosting the production of diabetes and obesity medications in the United States. This move comes as a response to the global rise in these conditions, necessitating increased production capacities to meet growing demand. The focus on injectable drug devices emphasizes efforts to improve drug delivery systems, ultimately enhancing patient compliance and therapeutic outcomes. Sanofi's financial outlook for 2026 is promising, driven by robust sales of Dupixent, which exceeded €5 billion in quarterly sales. Dupixent, a monoclonal antibody used for treating atopic dermatitis and other autoimmune conditions, has been a significant revenue driver for Sanofi. The success of Dupixent reflects its effectiveness and strong market adoption, highlighting the potential of monoclonal antibodies as cornerstones of modern pharmacotherapy, particularly for chronic inflammatory diseases. Regeneron and Sanofi's Dupixent continues performing strongly with $6 billion in sales during Q2 2026—marking its largest quarterly revenue since the pandemic began—illustrating robust demand across various indications within both companies' portfolios. On the regulatory front, Alfasigma's Linerixibat (Lynavoy) has received a positive opinion from the CHMP for treating cholestatic pruritus in primary biliary cholangitis following successful Phase 3 trials. As an IBAT inhibitor targeting bile acid metabolism pathways, Lynavoy introduces a novel therapeutic approach for managing symptoms associated with this autoimmune liver disease. Meanwhile, ImmunityBio's Anktiva has gained marketing authorization in the UAE for non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. Anktiva, an IL-15 cytokine-based protein therapy, exemplifies the growing interest in harnessing immune system modulators for cancer treatment. Takeda's recent decision to discontinue its nanoparticle therapy (TAK-101) for celiac disease highlights the inherent challenges in developing new therapies for autoimmune disorders. The disappointing Phase 2 results suggest that achieving immune tolerance to dietary gluten remains a significant scientific hurdle. From a strategic perspective, Sanofi's CEO has emphasized stricter go/no-go decisions during Phase 3 clinical trials amid pipeline cuts and significant impairment losses. This approach could lead to more efficient resource allocation and potentially higher success rates for late-stage drug candidates. The industry is witnessing significant transformations through strategic shifts driven by executives like Sanofi's new CEO Belen Garijo. Her vision includes reversing recent challenges faced by Sanofi by capitalizing on its strengths while addressing setbacks such as discontinuing certain late-stage clinical programs like the joint venture with Regeneron on the IL-33 candidate itepekimab. This strategic pivot mirrors broader industry trends toward optimizing late-stage pipelines to enhance competitive positioning and drive future growth. Advancements in AI-powered drug discovery continue gaining momentum through collaborations like those between GSK and Relation Therapeutics, alongside Causaly and Sage. These partnerships aim to leverage AI and machine learning technologies to accelerate drug discovery processes by integrating vast amounts of scientific literature into data analytics platforms. GlaxoSmithKline's $110 million deal with an AI biotech firm further signals increased integration between artificial intelligence technologies and pharmaceutical research efforts aimed at enhancing dataset quality thereby accelerating innovation throughout drug discovery processes. Bristol Myers Squibb faces further delays regarding its Alzheimer's psychosis treatment Cobenfy—a postponement reflecting ongoing complexities related to neurological drug development which requires overcoming high scientific hurdles alongside regulatory scrutiny. Alnylam Pharmaceuticals recently experienced a 29% drop in stock value following disappointing sales of Amvuttra and a downward revision of its ATTR franchise outlook for 2026. Such fluctuations highlight volatility within biotech investments when market expectations are not met. These collective developments reveal significant trends shaping today's pharmaceutical landscape: strategic pipeline optimization efforts alongside robust investment initiatives targeting high-demand therapeutic areas—all while leveraging technological advancements like AI integration aimed at improving R&D efficiency ultimately impacting patient care worldwide through innovative therapies addressing unmet medical needs globally.Support the show

In the newest edition of Oncology On the Go, Joshua Richter, MD, and Marco Davila, MD, PhD, spoke about the current multiple myeloma treatment landscape and highlighted practical considerations for administering CAR T-cell therapy to patients. Their discussion touched upon several critical subtopics ranging from optimizing operational and referral workflows to dismantling barriers to treatment access in rural settings.When it comes to navigating the multiple myeloma treatment algorithm, both hosts emphasized early evaluation to determine patient suitability for CAR T-cell therapy, which may help identify those who are most likely to experience the greatest responses with minimal toxicity. Regarding the question of sequencing different modalities, Richter pointed to data demonstrating the utility of administering CAR T-cell therapies prior to bispecific antibodies.Acknowledging that the average patient enrolled on a clinical trial may not align with what is typically seen in real-world practice, the hosts discussed “reassuring” data that those who do not meet certain eligibility criteria may nevertheless benefit from CAR T-cell therapy. Additionally, on the topic of maintaining an effective referral relationship between community oncologists and CAR-T centers, Davila noted that academic cell therapy clinicians may have an incumbent responsibility to consider how to improve access to treatment and make it easier for others to refer patients to care.“CAR T-cell therapy is now deeply entrenched in the world of relapsed multiple myeloma [and] soon to be likely entrenched in the newly diagnosed world. These are therapies that I think we're all going to need to embrace whether it's from an academic standpoint or a community standpoint,” Richter concluded. “Having that ongoing communication back and forth, especially as the field is moving so quickly, is absolutely key in providing optimal care for our patients.”Richter is an associate professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute, as well as the director of Multiple Myeloma at the Blavatnik Family - Chelsea Medical Center at Mount Sinai. Davila is the senior vice president and associate director for Translational Research, a professor of Oncology, chief of Lymphoma/Multiple Myeloma Service, and Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center.

Join Valerie Abraham as she shares how her upbringing in France, life in America, and marriage to her Egyptian American husband have shaped her unique approach to cooking and hospitality. From Sunday morning coffee and pastries to practical table décor on a budget (including dollar store dishes!), Valerie offers inspiring ideas, kitchen must-haves she uses daily, three favorite book recommendations, and a flavorful menu influenced by multiple cultures. She also reminds us that hospitality is an imitation of God, the ultimate giver of every good gift. We close with a moving, thought-provoking conversation about both giving and receiving hospitality during a season of grief. We're so glad you're here! Visit www.comeoverfordinner.com for recipes, product links, and more!

In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy.   Key topics discussed included: The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma Treatment selection based on patient age, prior therapy, drug exposure, and disease biology The importance of shared decision-making and incorporating patient preferences into treatment planning Recent clinical trial data and emerging therapies shaping the future of multiple myeloma care This episode provides practical insights into managing early relapsed/refractory disease and navigating today's evolving treatment landscape.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/    Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology. #MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology

Welcome to Omni Talk's Retail Daily Minute, sponsored by R&S Logistics, Duvo and Mirakl.In today's Retail Daily Minute, Omni Talk's Chris Walton discusses:Ahold Delhaize USA partners with Pear Commerce to connect shoppable recipes and product discovery directly to online carts across Food Lion, GIANT, Giant Food, Hannaford, and Stop & Shop.Kroger rolls out a new AI Shopping Assistant across its banners, letting shoppers plan meals, build carts by budget and diet, and turn a photo or URL into a cart instantly.Macy's takes down its beloved red shopping bag billboard in Herald Square after more than 30 years, with new branding for the flagship promised soon.The Retail Daily Minute has been rocketing up the Feedspot charts, so stay informed with Omni Talk's Retail Daily Minute, your source for the latest and most important retail insights.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Pierre-Yves Dumas and Samik Basu on their latest articles published in Blood. Dr. Dumas talks about "Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy" where the team was able to identify that ultra-low-burden FLT3-ITD microclones are associated with higher relapse risk and inferior relapse-free survival. Their work encourages the evaluation of FLT3 inhibitor strategies. Dr. Basu discusses "CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial". In four patients, the treatment was well tolerated and supported CAR T-cell expansion and persistence, challenging the need for lymphodepletion and supporting chemotherapy-free approaches in autoimmune disease.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Biogen has made a significant acquisition by purchasing Apellis Pharmaceuticals, a move expected to boost its 2026 revenue guidance with promising growth prospects. This strategic acquisition, along with strong sales from new drugs, enhances Biogen's position in the competitive market for neurological disorders. By integrating Apellis' offerings, Biogen is poised to strengthen its portfolio, particularly in areas of unmet medical need. On the regulatory front, AbbVie has achieved a milestone with its drug Rinvoq (upadacitinib), which has received dual approvals from the European Union for treating non-segmental vitiligo and severe alopecia areata. These approvals were based on successful Phase 3 data, underscoring Rinvoq's efficacy as a JAK inhibitor in tackling autoimmune conditions. This development not only highlights AbbVie's commitment to expanding its therapeutic portfolio but also positions upadacitinib as a potential mainstay treatment for dermatological autoimmune diseases. AstraZeneca Pharma India has secured approval from the Central Drugs Standard Control Organization for Enhertu (trastuzumab deruxtecan) in the neoadjuvant setting for HER2-positive early breast cancer. This approval marks a significant advancement in personalized cancer therapy, offering new hope for patients with this aggressive form of breast cancer. In terms of industry collaborations, the landscape is witnessing numerous partnerships and strategic alliances that are driving innovation forward. Skyverna Therapeutics and ElevateBio have entered a five-year clinical and commercial supply agreement for autoimmune CAR-T therapy, reflecting the growing interest in cell therapies for rare diseases. Meanwhile, Vertex Pharmaceuticals and AbCellera have joined forces to accelerate drug discovery in autoimmune T-cell engagement, supported by a $28 million upfront investment. These collaborations emphasize the importance of combining expertise and resources to advance complex therapeutic solutions. The integration of artificial intelligence in drug development continues to gain momentum. Evinova and Merck KGaA's strategic collaboration aims to leverage AI and machine learning to enhance clinical trials' efficiency, potentially ushering in a new era of precision medicine. Such partnerships highlight the transformative potential of AI in streamlining research and development processes. In funding news, Core Biomedicine has secured $21 million in Series A financing to advance its precision oncology therapeutics. Enlivex's substantial $400 million private placement aims at advancing prediction markets treasury and Allocetra immunotherapy, further accentuating the focus on personalized medicine targeting specific cancer pathways. Clinical trials have also delivered promising results. ProMIS Neurosciences reported positive interim safety and biomarker data from its Phase 1b study of PMN310 for Alzheimer's disease. This monoclonal antibody targets amyloid-beta oligomers implicated in Alzheimer's pathology, offering hope for patients with this debilitating disorder. Mergers and acquisitions remain active, exemplified by Caldera Therapeutics' reverse merger with Synlogic alongside $278 million in financing to advance its bispecific antibody for inflammatory bowel disease. This move reflects a broader trend toward consolidating resources to tackle complex autoimmune conditions. Eli Lilly's ascent to the top of Norstella's pipeline-to-patient productivity index is noteworthy, driven by successful launch strategies and rapid development cycles. This achievement underscores Eli Lilly's effective alignment of R&D efforts with market needs, particularly in areas such as GLP-1 receptor agonists that have transformed diabetes care. Teva Pharmaceuticals is demonstrating resilience through its innovative medicines portfolio amidst declining generic sales. The unexpected surge in Ajovy sales highlights Teva's pivot toward high-value branded drugs amidst competitive pressures. Novo Nordisk faces legal challenges as it navigates allegations regarding Cagrisema's Phase 3 study protocol changes. Legal scrutiny around transparency in clinical trial disclosures continues to highlight the importance of ethical practices and investor trust. Collectively, these developments illustrate a vibrant yet challenging environment where scientific advancements in immunotherapy and targeted treatments intersect with strategic business alignments focused on sustainable growth. As these trends unfold, they promise more effective treatments for complex diseases while companies adapt to an evolving market environment demanding agility and foresight. As always, stay tuned to Pharma Daily for more insights into how these transformations continue to shape the future trajectory of drug development and healthcare delivery globally.Support the show

⏱️ Capítulos do vídeo00:00 Cartão Black na Sala VIP00:21 Como escolher um cartão de crédito01:12 Os três níveis analisados01:45 Santander Unique03:53 XP Visa Infinite04:46 Santander Unique ou XP Visa Infinite?05:24 Caixa Ícone Visa Infinite07:11 BB Altus Liv08:33 Caixa Ícone ou BB Altus Liv?09:21 Bradesco Amex The Centurion Card10:58 Itaú Private World Legend Mastercard12:08 Centurion ou World Legend?12:52 Qual é o melhor cartão de 2026?13:37 RC Wealth e RC Club

Send us Fan MailPediatric cancer is a gut punch most people can't look at for long, and that discomfort has a cost. We sit down with Dr Dean Lee, Professor of Pediatrics at The Ohio State University and Nationwide Children's Hospital, to talk about why kids' cancer research is still massively underfunded and why community-driven giving is not a feel-good extra. It's often the only way the next breakthrough gets its first chance.We unpack the hard truth behind the pediatric cancer funding gap: fewer patients means fewer commercial incentives, and “trickle-down” solutions from adult oncology don't always fit the diseases kids actually face. Dean explains why childhood cancer can be oddly invisible day to day, even though it remains a leading cause of death in children outside of accidents, and why foundations like Cancer Free Kids step in to fund the science that government grants won't touch early on.Then we get into hope with specifics. Dean walks us through what's changing in cancer immunotherapy and cellular therapy, including why CAR T cell therapy was a game-changer in leukemias and lymphomas and why solid tumors have been so much harder. We also talk about what pilot grants really do, how a $50,000 award can create the preliminary data needed for major funding, and a real example involving CRISPR and natural killer cell research that grew into a much bigger research platform.Join us for the third annual Little Legends Lemonade:

The CEO of New Zealand's biggest independent medical research organisation, the Malaghan Institute, says the ongoing challenge of funding the organisation keeps her up at night. Professor Kjesten Wiig oversees research into groundbreaking cancer treatments and RNA technology, but says it's juggling the institutes' sources of income that remains a constant concern. In 2015, for example, 61 percent of the institutes' income came from government grants, but last year that had fallen to just 26 percent, even as Malaghan brings the game-changing CAR T-cell cancer therapy ever closer to New Zealand patients.

In this episode of Hema Now, Megan Melody speaks about the evolution of CAR-T cell therapy and its impact on lymphoma care. She explores the major advances that have transformed outcomes for patients with relapsed and refractory disease, the unanswered questions shaping current research, and the practical challenges of building successful cellular therapy programmes. The conversation also covers equitable access to treatment, the role of quality standards and accreditation, personalised approaches to CAR-T therapy, and the importance of physician leadership and mentorship in shaping the future of academic haematology. Timestamps:   00:00 – Introduction   01:13 – Journey into Haematology and Lymphoma   04:19 – Major Advances in CAR-T   06:00 – Unanswered Questions After CAR-T   07:45 – Building Successful Cellular Therapy Programmes   09:06 – Improving Access to CAR-T   12:55 – Evolving Standards in Cellular Therapy   14:16 – Towards Personalised CAR-T Treatment   16:00 – Physician Leadership in Academic Medicine   17:10 – Career Advice for Future Specialists   19:02 – Future Directions in Cellular Therapy 

O Bingo do Wanda voltou e, dessa vez, vocês vão conhecer quem está por trás do hit que é a página Saquinho de Lixo. Por isso, o tema do bingo é “O quão cronicamente online você é?”.Para todos os pais que falam que não precisam de nada, mas na verdade estão precisando de tudo: ofertas de até 70% OFF, até 21x sem juros com cartão Mercado Pago e muito mais só no Mercado Livre. Corre pro app fazer comprittas: https://bit.ly/4ptbdtcCampanha válida até 09/08/2026. Cartão de crédito sujeito à aprovação. Parcelamento elegível a produtos selecionados. Veja condições do Vale Troca em mercadolivre.com.br/l/valetroca. Ver mais condições em Dia dos Pais.==============FAÇA PARTE DO CLUBINHO WANDA!Episódios extras toda segunda e sexta a partir de R$10!Apoiase: https://apoia.se/podcastwandaOrelo: https://orelo.cc/wandahttps://linktr.ee/podcastwandaCAÇADORES DA CULTURA PERDIDASITE: dolls.com.brFILME: Missão Madrinha de CasamentoBLOG: Vodca BarataEpisódio apresentado por:Phelipe Cruz: https://www.instagram.com/phelipecruz/Samir Duarte: https://www.instagram.com/eusousamir/Saquinho de Lixo: https://www.instagram.com/saquinhodelixo/Episódio apresentado por:@phelipecruz@eusousamir@saquinhodelixoProdução:Julia Gomes (julia@papelpop.com / @g0mesjulia)Edição / Captação:Felipe Dantas (dantas@papelpop.com / @apenasdantas)Toda quarta-feira, 20h, ao vivo no Youtube e em todas as plataformas de streaming.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wealth of significant advancements and strategic moves shaping the industry landscape. AstraZeneca is making waves with its steadfast commitment to reaching an $80 billion revenue target by 2030. This ambitious goal is underpinned by strong sales in oncology and rare disease treatments, despite some setbacks with underperforming drugs like Ultomiris. The company's confidence is further reflected in its robust internal pipeline of antibody-drug conjugates (ADCs), even after discontinuing two candidates that fell short in clinical trials. This move highlights an industry-wide focus on high-potential therapeutic areas, underscoring the critical role of sustained innovation in preserving market leadership. In leadership news, Sarepta Therapeutics has appointed Michael Severino as CEO, succeeding Doug Ingram. Severino's extensive experience from AbbVie and Tessera signals a strategic shift for Sarepta, especially as it hones its focus on therapies for Duchenne Muscular Dystrophy. Leadership transitions like this can significantly impact a company's strategic direction, potentially steering it toward new therapeutic breakthroughs. On the regulatory front, Otsuka's Simtriyo has received FDA approval, marking it as a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD. This approval is a major leap forward in central nervous system therapeutics, offering a non-stimulant option that could become a blockbuster drug in this underserved market. Such advancements highlight the persistent need for innovative treatments in CNS disorders. Similarly, Outlook Therapeutics has achieved FDA approval for Lytenava, a reformulated version of Roche's Avastin for wet age-related macular degeneration (AMD). This victory, following three prior rejections, exemplifies the challenges and opportunities inherent in drug reformulation and regulatory perseverance. Corporate acquisitions continue to shape industry dynamics. Argenx's acquisition of Forte Biosciences for $2.2 billion exemplifies strategic investments aimed at expanding therapeutic portfolios. Forte's promising Phase 2-stage vitiligo drug acquisition underscores the industry's shift towards biologics in managing complex autoimmune disorders. Amgen's recent layoff of approximately 40 employees aligns with broader trends of operational optimization amidst organizational restructuring. Such workforce adjustments often reflect shifts in business strategy or responses to evolving market conditions. In clinical development news, InnoCare Pharma has announced successful Phase 3 results for its oral TYK2 inhibitor Fadeucravacitinib in treating moderate-to-severe plaque psoriasis. This achievement underscores the potential of targeted therapies in addressing autoimmune conditions by modulating specific signaling pathways. The FDA's approval of Freenome's SimpleScreen CRC blood test marks a significant advancement in non-invasive diagnostic tools for colorectal cancer screening. Such innovations could dramatically impact early cancer detection and improve patient outcomes. Meanwhile, emerging insights into CAR-T therapy have identified genetic markers linked to toxicity risks in Yescarta patients. These findings can guide future CAR-T product development towards enhanced safety profiles, offering pathways for engineering safer therapies by identifying patients at higher risk for adverse effects. Finally, the partnership between Salesforce and Veterans Affairs aims to integrate AI into healthcare workflows, illustrating the increasing role of digital transformation in enhancing healthcare delivery and operational efficiency. These developments highlight the ongoing evolution towards more personalized and efficient healthcare solutions within the pharmaceutical and biotech sectors. As companies navigate complex regulatory landscapes, pursue innovative therapies, and adapt to dynamic market demands, their efforts are poised to advance patient care standards and drive future growth within these critical industries. The implications for patient care are profound, as new treatments offer hope for conditions that have long eluded effective intervention. Stay tuned with Pharma Daily as we continue to bring you the latest updates from this rapidly evolving field.Support the show

Konichiwa amikos de animenkai, un lunes mas de puro hype a su lado, en esta ocasión una dupla que hace mucho no veían... Azura y Alan hablando de unas noticias muy curiosas, nueva economía y moneda detectada, la universidad de silicon valley le paga a los gamers? todo esto y mucho mas en este nuevo episodio, !no se lo pueden perder!

This month, the gals are joined by fellow podcaster and friend IRL Aaron Schoenrock to discuss clumsy robots, spilled hot sauce, Ohio's most awkward Chili's, nasty pro athletes, cadaver otters, and the grouchiest kitty in all of heaven. Tune in for July's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

More investigation into the strange sets of "cart ruts" we explored in the Phrygian Valley in Turkey. We show more drone footage and photos, look at examples of "cart ruts" from the "Oregon Trail" in Wyoming, as well as actual ruts in mud for comparison. We read more emails with suggestions and ideas and discuss them.Thank you all for your emails and comments! The ruts are a fascinating and enduring mystery.Support us on Patron or PayPal by going through our support page here: https://www.brothersoftheserpent.com/support

Gálatas 4:29 "Pero como entonces el que había nacido según la carne perseguía al que había nacido según el Espíritu, así también ahora. " Quiero invitarlos a analizar la historia y meternos en la intimidad de una de las familias más conocidas de la Biblia: La familia de Abraham y Sara:Dios les había dado una gran promesa, pero los años pasaban y nada que se cumplía. Así que, en medio del desespero, decidieron hacer lo que muchos de nosotros hacemos hoy en día: intentar "ayudarle" a Dios con una solución puramente humana.De esa decisión nace Ismael. Fue un hijo producto de la carne, del afán y de la lógica humana, no del diseño del Espíritu. Sara y Abraham armaron una solución que, por encima, parecía resolver el problema, pero que en el fondo era frágil y trajo mucho dolor tanto en la vida de Sara como también en la vida a Agar. Construyeron una solución "de cartón". Y las consecuencias de intentar forzar las cosas en sus propias fuerzas, en lugar de esperar la promesa de Dios, generaron conflictos familiares tan profundos que aún en el día de hoy podemos ver las consecuencias.Precisamente sobre este contraste entre lo que hacemos en nuestras fuerzas y lo que Dios hace a través de su Espíritu, es que el apóstol Pablo nos habla hoy en su carta a los Gálatas: "Pero como entonces el que había nacido según la carne perseguía al que había nacido según el Espíritu, así también ahora." — Gálatas 4:29 (RVR1960)Es interesante ver los dos planos que el apóstol Pablo propone para llevar a los gálatas a reflexionar; los lleva a analizar cuándo algo proviene del Espíritu y cuándo algo proviene de la carne.Por eso, me centré en este pasaje para estudiar un poco a esta familia, ya que el apóstol Pablo la trae a colación. Vamos a revisar los peligros que amenazan a las familias, esos desafíos por los cuales todos atravesamos en estos tiempos.A menudo nos enseñan cómo construir una familia, cómo formarla y cómo convivir en ella, pero solemos perder de vista los errores que nosotros mismos generamos. A veces queremos que nuestras familias mejoren y sean transformadas, pero los cambios que proponemos son meramente humanos; y cuando son de origen humano, lastimosamente no son permanentes, sino pasajeros.Lo explico de esta manera: si intentas imponer reglas en tu hogar motivado por la ira, el resentimiento o el mal carácter, tal vez consigas resultados temporales, pero no lograrás un cambio real. Podrás infundir temor, pero nunca una verdadera transformación. Y cuando escudriñamos la Palabra para entender por qué sucede esto, descubrimos una gran verdad que hoy quiero compartir contigo y con todas las familias que me escuchan: la única forma de que un hogar sea verdaderamente transformado es a través del Espíritu Santo.Podemos acumular riquezas, alcanzar un alto nivel educativo, tener prestigio social o mucho reconocimiento, pero hoy vengo a decirte que la única manera de edificar una familia sólida es mediante el poder del Espíritu Santo.Si deseas tener una buena familia, necesitas a Cristo. Todo lo demás es bienvenido (los recursos económicos, que tus hijos estudien en un excelente colegio o en una gran universidad), pero absolutamente nada podrá reemplazar la presencia de Dios en un hogar. Cuando permites que la presencia de Dios reine en tu casa, tendrás una familia bendecida para Su gloria. Si Cristo está en la casa, la familia avanza. Cuando Cristo gobierna el hogar, este trasciende hacia el propósito que Dios ha trazado para él. A la manera de Dios o a mi maneraAhora, ¿qué pasa cuando los cambios y la transformación en una familia no nacen del Espíritu? Entonces provienen de tus opiniones, provienen de tu crianza. Muchas veces decimos: "Es que así me criaron a mí". Entonces, como tu papá cogía un palo, tú ya también tienes un palo; y como tu mamá tenía una chancla, tú también andas por ahí armado con una chancla en la cintura porque así te criaron. Hoy no vine a hablarte de tu crianza, hoy vine a hablarte del poder del Espíritu de Dios para que transforme a la familia. No vine a hablarte de lo que viviste en los tiempos de tus abuelos, vine a decirte que Dios está interesado en tu familia para traer una transformación a través del Espíritu, y no por métodos humanos.Cuando permites que Cristo intervenga en tu familia, entonces ya no serán tus opiniones ni tus emociones las que manden, porque actuar bajo nuestras emociones hace que, en lugar de arreglar las cosas, empeoren mucho más. Lo que nace de la carne se daña, pero lo que es del Espíritu permanece. Por eso te decía que esos cambios que hacemos en nuestra carne, si son normas, están muy bien, pero hay que ungirlas con el Espíritu Santo en oración, hay que pedir que Dios nos guíe y nos hable para que las cosas realmente puedan mejorar, porque cuando lo haces solo a tu manera, el hogar va por un camino en cierta temporada y por otro muy distinto en otra.Veo en la Biblia que el apóstol Pablo menciona a Isaac y a Ismael para hacer el paralelo entre cuando Dios mete la mano y cuando el hombre mete la mano. Si hemos traído al psicólogo para que nos ayude en casa, no está mal. Si hemos acudido al médico, no está mal; o al arquitecto... Hacemos tantas cosas por nuestra casa en lo físico, en la estructura, en lo mental y en lo emocional. Pero hoy vine a decirte: invita a Cristo a que viva en tu casa, no solo a que la visite. Cuando Cristo vive en la casa, a la casa le va bien, es bendecida, los hijos son bendecidos, el matrimonio es bendecido. No a tu manera, sino a la manera de Dios.Como un ejercicio pedagógico y para que lo recuerdes, quiero que lo pienses así: vamos a definir si en nuestra casa estamos haciendo las cosas a la manera de Dios o a tu manera. Tenemos la tendencia a querer hacerlo a nuestra manera, nos gusta, entonces nos imponemos y decimos cosas como: "¡Aquí se va a hacer así!". Ese tipo de actitudes demuestran que en esa casa se están haciendo las cosas a tu manera. Y hoy te estoy hablando de hacerlas a la manera de Dios.  El Gobierno del Espíritu en el HogarCuando estaba estudiando un poco la historia de Isaac e Ismael, yo decía: "Señor, ¿cómo es posible que estos dos nunca pudieron estar en paz?". Ismael venía de un actuar de la carne, y ese actuar siempre terminó persiguiendo a lo que venía del Espíritu. Cuando en una casa no se le entrega el gobierno a Dios para que el Espíritu de Dios la gobierne, entonces otras cosas comienzan a gobernar: no gobierna el Espíritu de Dios, gobierna tu temperamento; no gobierna el Espíritu de Dios, gobiernan tus ideas o lo que tú quieres.Hoy vengo a decirte que, cuando el Espíritu Santo está en tu vida, lo que va a gobernar no son tus deseos, sino los frutos del Espíritu Santo. Podrás tener amor por tus hijos, habrá gozo y paz en el entorno. Ve, estudia los frutos del Espíritu, y te darás cuenta de lo que es una verdadera familia y una verdadera casa. Porque cuando una familia se construye sin Dios, termina luchando contra lo que viene de Dios.A una familia que no está construida por el Señor no le gusta orar, porque eso viene del Espíritu. No le gusta hacer el devocional, porque eso viene del Espíritu. No le gustan las normas ni hacer lo correcto, porque eso viene del Espíritu. Entonces los hijos quieren entrar a la hora que les da la gana a la casa, porque eso no viene de Él, viene de cómo se está manejando nuestra casa según la carne. "Es que todos los amiguitos en el colegio...", para ahí. "Es que en la universidad se hace...", pero es que nuestra casa no puede estar ...

At the 2026 National ICE-T Conference in Orlando, CancerNetwork® sat down with a variety of expert researchers and clinicians to discuss the latest developments in immune effector therapy across different hematologic oncology populations. Sessions at the meeting covered practical considerations for integrating CAR T-cell therapies, bispecific antibodies, and other modalities into the treatment of those with multiple myeloma, lymphoma, and other hematologic malignancies.First, Benjamin Diamond, MD, an assistant professor of Clinical Medicine, a member of the Sylvester Myeloma Institute, and a member of the Myeloma Genomic Lab at the University of Miami Miller School of Medicine, spoke about his presentation reviewing bispecific antibodies for the management of multiple myeloma. In his session, Diamond stated that bispecific T-cell engagers are altering the landscape of multiple myeloma care and will eventually become an option in the frontline setting. With many products to choose from, Diamond emphasized sequencing these novel therapies wisely and stressed aggressive infection prophylaxis as a mandatory facet of care.Next, Tiba Al Sagheer, PharmD, BCOP, BCACP, a pharmacy quality improvement coordinator for transplant and cellular therapy at Miami Cancer Institute of Baptist Health South Florida discussed her presentation focused on defining new thresholds for monitoring and mitigating toxicities associated with CAR T-cell therapy. She described considerations for balancing early toxicity intervention against the risk of blunting efficacy depending on the specific CAR T-cell product used during treatment. Ultimately, she noted that that there is still no definitive answer or threshold for initiating prophylaxis for toxicity associated with CAR T, and that differentiating between immune effector cell (IEC)–associated hemophagocytic lymphohistiocytosis (HLH)–like syndrome (IEC-HS) and cytokine release syndrome (CRS) represents an ongoing challenge in the field.Finally, Nikesh N. Shah, MD, and Carlos Silva Rondon, MD, shared their perspectives on a debate regarding the roles of bispecific antibodies and CAR T-cell therapies in relapsed/refractory follicular lymphoma. In his presentation, Shah, a hematologist-oncologist at Tampa General Hospital who specializes in hematologic malignancies, including aggressive lymphomas and acute lymphoblastic leukemia, took the position that bispecific antibodies should be used prior to CAR T-cell therapy for most patients, although both treatments have utility in the field. Silva Rondon, a hematologist, oncologist, and bone marrow transplant specialist at Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System/Memorial Cancer Institute in Pembroke Pines, advocated for CAR T-cell therapy during the debate but acknowledged that both modalities can make up a complementary strategy for overcoming relapsed/refractory follicular lymphoma.References Diamond B. Bispecific antibodies for the management of multiple myeloma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Sagheer TA. Thresholds and therapeutics: a precision approach to CAR T toxicity management. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Shah N. Debate: bispecific antibodies vs CAR-T in follicular lymphoma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL. Silva C. CAR-T cell therapy for relapsed follicular lymphoma. Presented at the 2026 National ICE-T Conference; July 18, 2026; Orlando, FL.

ORIGINAL AIR DATE: JUNE 27, 2024Michael Collins from Wandering Wolf Productions joins us in studio to discuss his travels around the world to visit ancient and mysterious sites in Peru, China, Malta, Easter Island and more. We discuss the mystery of the cart ruts of Malta and how they compare to the ones we investigated with him in Austin, Texas. We also talk quite a bit about his travels in China, the infamous Yanshan Quarry and the Longyou Grottoes.You can find Michael's website here:https://www.wanderingwolfproductions.com/Subscribe to his youtube channel here:https://www.youtube.com/@WanderingWolf

Join Scott as he tests the gameboy cart's functionality before ordering a new rev. Thanks to dcd for timecodes: 0:00 Getting started 0:42 Hello everyone, welcome, introduction to Adafruit 1:42 Feather esp32-s3 example circuit python (CP) microcomputer 3:05 CP GB cartridge pygp2350 4:30 adafruit_gameboy.py driver 5:24 changes to the gp cartridge schematic 7:00 explore the unfinished PCB layout 9:32 JLCPCB parts page ( for micro sd card ) 12:01 GB startup with LLM generated demo 16:00 dive into the common-hal/_gpio/__init__.c code and adafruit_gameboy.pas 26:09 next week - get back to hardware in the loop topics 27:00 vibe code code.py for pygb 2350 - test the midi 29:26 also test audio in parallel 30:00 uart loopback test 42:00 "Hopefully the last revision before we can sell it" :-) 50:00 GB color should work 57:00 debug the opto isolator 1:02:33 wrapping up Visit the Adafruit shop online - http://www.adafruit.com ----------------------------------------- LIVE CHAT IS HERE! http://adafru.it/discord Subscribe to Adafruit on YouTube: http://adafru.it/subscribe New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ -----------------------------------------

Originally aired 2/7/2023Introducing ZOUK'S CUBES – a new podcast from the creators of Add to Cart! Jason Mantzoukas is taking over the feed to bring Ku and Su on an unforgettable journey into the world packing cubes, pouches and backpacks. It's a meeting of the minds for Kulap, as her two besties Jason and SuChin hit it off at first, thanks to their shared love of wool socks and arch support. But things take a quick turn when Zouk's gear threatens the chaos Su thrives on. Forget everything you've heard so far, this is episode zero. Please note, Add To Cart contains mature themes and may not be appropriate for all listeners. To see all products mentioned in this episode, head to @addtocartpod on Instagram. To purchase any of the products, see below. Jason and Su share a deep love of Darn Tough SocksThe Birkenstock Zermatt slipper is so good, Jason bought severalThese small bags from Tom Bihn and Evergoods make going through TSA a breezeThis Evergoods backpack is carry-on and under-the-seat sizeBut wait, there's more backpacks: bellroy's Transit Backpack, and the Synik 30 and Shadow Guide 33 from Tom BihnThis Nitecore Powerbank can charge Jason's phone three times in one goThe stars of Zouk's Cubes are these Peak Design Packing CubesThe cherry on top of Jason's organizational system: little plastic baggiesCan't stand the Monopoly board game? Try the card game (pst, get the green pack)Jason nerds out about the Star Wars: Thrawn Series (and the Audible version too)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BloodCancerTalks: ASCO/EHA 2026 Lymphoma Round-Up with Dr. Thomas LewGuest: Dr. Thomas Lew, Peter MacCallum Cancer Centre (Melbourne, Australia) — hematologist specializing in lymphoid malignancies.In this episode, we break down the biggest lymphoma and CLL data from ASCO and EHA 2026 (Chicago and Stockholm), covering mantle cell lymphoma genomics, bispecific antibodies in DLBCL and follicular lymphoma, a practice-changing (or not) CNS prophylaxis study, transplant-eligible relapsed DLBCL, fixed-duration BTK/BCL2 combinations in CLL, and the first in vivo CAR T data in lymphoma.1. TRIANGLE: TP53-Mutated MCL Molecular Subgroup AnalysisMolecular subgroup data from the practice-shaping TRIANGLE trial presented by Dr. Marta Grau.Discussion: Where TP53-mutated MCL stands today, and whether ibrutinib-containing regimens are changing the natural history of this historically dismal subgroup.2. EPCORE DLBCL-1: Epcoritamab vs. Chemotherapy in R/R DLBCLRandomized phase 3 trial (n=483) of bispecific antibody epcoritamab vs. investigator's choice chemotherapy (72% R-GemOx, 28% BR) in second-line-or-later, transplant-ineligible R/R DLBCL, presented by Prof. Chris Fox.Discussion: A PFS benefit without an OS signal, set against a meaningfully higher infection-related mortality — what this means for patient selection and infection mitigation strategies.3. CNS Prophylaxis in Ultra-High-Risk DLBCL: Does HD-MTX Help?Pooled analysis of two large multicenter retrospective cohorts (n=1,923 ultra-high-risk patients — CNS-IPI 5–6, testicular/renal/adrenal/breast involvement, or ≥3 extranodal sites), presented by Dr. Matt Wilson (Glasgow) and simultaneously published in JCO. Discussion: Whether these data close the door on routine HD-MTX in ultra-high-risk DLBCL, and if any subgroup still warrants prophylaxis.4. Pola-R-ICE: A Negative Trial in Transplant-Eligible R/R DLBCLRandomized phase 3 study (4 European cooperative groups; n=294) of polatuzumab vedotin added to R-ICE in transplant-eligible R/R DLBCL, with ASCT/alloSCT/CAR-T permitted as consolidation.Discussion: Why this trial missed, and what it tells us about the ceiling of intensive salvage chemo-immunotherapy platforms in the CAR-T era.5. BRUIN-CLL-322: Fixed-Duration Pirtobrutinib + Venetoclax-Rituximab in R/R CLLRandomized phase 3 trial (n=639) of fixed-duration pirtobrutinib (non-covalent BTKi) plus venetoclax-rituximab (PVR) vs. venetoclax-rituximab (VR, the MURANO-based control) in second-line-or-later R/R CLL.6. SOUNDTRACK-F1: Surovatamig (CD19 Bispecific) Safety Run-In in Untreated Follicular LymphomaSafety run-in from a randomized trial (surovatamig vs. chemoimmunotherapy) in untreated FL meeting GELF criteria, presented by Prof. Chan Cheah — building on EPCORE-FL-1 data presented at ASH.Discussion: How this CD19-directed bispecific compares to CD20-targeting agents in frontline FL.7. LB2501: First In Vivo CAR T Data in B-Cell LymphomaLate-breaking data from Dr. Lei Fan and Legend Biotech on LB2501, an in vivo CD19/CD20 dual-targeted CAR T therapy — a third-generation, self-inactivating, replication-incompetent lentiviral vector that generates CAR T cells directly in vivo, without lymphodepletion. Builds on the in vivo CAR T myeloma data first presented at ASH and updated at EHA.Discussion: What these very early but striking data suggest about the feasibility of in vivo CAR T generation in lymphoma, and how it might reshape access to cellular therapy.BloodCancerTalks is co-hosted by Rajshekhar Chakraborty,  Ashwin Kishtagari and Eddie Cliff. Subscribe wherever you get your podcasts. 

A 10h, ce vendredi 24 juillet 2026, les GG : Sandrine Pégand, avocate, Zoran Spasojevic, restaurateur, et Jean-Loup Bonnamy, prof de philo, débattent de : "L'écart entre le brut et le net est un scandale", dit Gabriel Attal.

In this episode of “The Business of Blueberries,” Kasey Cronquist, president of the U.S. Highbush Council (USHBC) and the North American Blueberry Council (NABC), is joined by Dana Concepcion, senior director of fresh and frozen at Walmart Connect. Concepcion sits at the intersection of fresh merchandising and modern digital advertising. In her role, she drives advertising growth across some of the company's most strategic categories, partnering up with leading produce, meat, frozen and bread manufacturers to deliver data-driven, omnichannel marketing solutions. She joins the podcast to discuss aligning blueberry campaigns to seasonal supply fluctuations, leveraging co-branded recipe campaigns and measuring incremental growth.“ What makes our relationship so unique is that there's a real shared goal that we all have. It's a 360 collaboration between our team at Walmart Connect, the merchant and buyer teams at Walmart, the blueberry council, the growers, everyone all together, and the shared goal there is really growing overall blueberry consumption.” – Dana Concepcion Topics covered include: An introduction to Concepcion and her role with Walmart Connect.How Walmart Connect uses real-time shopper and purchase data across omni-channel ad formats.Opportunities to align blueberry campaigns to seasonal supply fluctuations, leveraging co-branded recipe campaigns.How Walmart measures incremental growth through sales lift, new-to-category buyers and repeat purchases.How Walmart uses in-store tactics like deli/bakery screens and product demos to drive impulse buying.Crop ReportThe Blueberry Crop Report is an update on crop conditions and markets throughout important blueberry growing areas. Today you'll hear from TJ Hafner in Oregon, Emilie Parkanzky in Michigan and Alan Schreiber in Washington. This was recorded on July 23, 2026.

In this informative episode we dived into the world of CAR T-cell therapies for multiple myeloma. In this ToxCheck episode, we focused on the available CAR-T options, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), and discussed their side effects, management strategies, and the importance of patient education.   We were joined by myeloma specialists Caitlin Costello, MD, from UC San Diego Health, and Joshua Richter, MD, from Mount Sinai, who shared their insights on the acute and chronic side effects associated with CAR-T therapies. Learn about the common toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), as well as the role of prophylactic treatments and the importance of bridging therapy.   This episode emphasized the critical collaboration between community oncologists and academic institutions to ensure patients receive the best care possible. Tune in to understand how to navigate the complexities of CAR-T therapies and empower your patients with the knowledge they need.   Key Topics: Overview of CAR-T therapies for multiple myeloma Common side effects: CRS and ICANS Management strategies for acute and chronic toxicities The role of prophylactic treatments Importance of communication between community and academic oncologists   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #CARTtherapy, #MultipleMyeloma, #CRS, #ICANS, #OncologyBrothers

Faturas mostram que o ex-presidente gastou mais de R$ 1 milhão com o cartão corporativo do clube durante cinco anos. O caso é investigado internamente. Enquanto isso, o São Paulo volta ao Brasileirão com derrota por 2 a 1 para o Athletico. Dá o play!

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Hanny Al-Samkari and Xin Zhou on their latest articles published in Blood. This episode highlights two important advances in hematology: the first report from the CHORUS registry for hereditary hemorrhagic telangiectasia (HHT) presented by Dr. Al-Samkari and also the introduction of the ASH Hematomics (ASHOP) platform for integrative genomic data analysis presented by Dr. Zhou. The CHORUS registry reveals that HHT is a progressive, underrecognized inherited bleeding disorder with a substantial burden of recurrent bleeding, iron deficiency, arteriovenous malformations, and life-threatening complications, while emphasizing the need for earlier diagnosis and the development of targeted therapies. The second presentation introduces ASHOP, an open-access platform that enables researchers to explore and integrate large-scale clinical and genomic datasets, facilitating discoveries in leukemia and other hematologic diseases through advanced analytical tools. Together, these studies demonstrate how comprehensive patient registries and innovative data-sharing resources are advancing precision medicine, improving disease understanding, and accelerating future research across hematology.

In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP, Clinical Pharmacy Specialist in the Stem Cell Transplantation and Cellular Therapy Department at The University of Texas MD Anderson Cancer Center, sits down with Lauren Campasano, MSW, LCSW, OSW-C, a licensed clinical social worker in New Jersey at Robert Wood Johnson Barnabas Health, to discuss the vital role social workers play throughout the CAR T therapy journey.Together, they explore how social workers help patients and caregivers navigate the complex medical, emotional, financial, and logistical challenges associated with CAR T therapy. From pre-treatment evaluation through post-treatment recovery, the conversation highlights the importance of multidisciplinary support in improving the patient experience and optimizing outcomes.The discussion covers:The role of social workers in CAR T patient assessment, caregiver support, and treatment readiness.Common psychosocial, financial, and logistical barriers patients face during CAR T therapy.Best practices for integrating social work into the multidisciplinary cellular therapy team.This episode offers valuable insights for clinicians seeking to better understand the critical contributions of social work to CAR T care and patient-centered cellular therapy programs. Listen to the episode below or on your favorite app. Subscribe to ASTCT Talks and share this episode with your colleagues to keep the conversation going.This episode was made possible through support from Johnson & Johnson.

De que maneira os novos testes rápidos e as tecnologias de ponta impactam a segurança do paciente e as condutas em ambiente hospitalar? Neste episódio do Afya News, apresentamos a descoberta da USP de um teste que detecta superbactérias em seis horas na UTI, agilizando decisões de isolamento e o uso racional de leitos. Abordamos também a importância da governança contínua em inteligência artificial hospitalar, destacando por que a supervisão direta de algoritmos é crucial para a segurança clínica e operacional. Por fim, detalhamos no Radar como a nanotecnologia está revolucionando a imunoterapia e o uso de células CAR-T contra o câncer. O Afya News apresenta notícias da medicina com informação confiável e atualizada no seu tempo. Criado pela Afya, o maior hub de educação e soluções para a prática médica do Brasil, nosso propósito é transformar a saúde junto com quem tem a medicina como vocação.Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/23-07-2026

Take a look at Joni's newest book: "Keeping Faith When Life Hurts." Order it here. --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

We discuss the mystery of the "cart ruts in stone" we visited while we were in Turkey; looking at video on the ground as well as drone footage of several large groups of well-preserved ruts in ancient volcanic tuff. Who made the ruts, when were they made, and how were they made? We address these questions and more, as well as reading emails from listeners who have their own possible answers.You can support us through Paypal or Patreon by heading over to our support page on our website: https://www.brothersoftheserpent.com/support

Picolé De Limão é um quadro do canal Não Inviabilize. Aqui você ouve as suas histórias misturadas às minhas!Use a hashtag #Protecao e comente a história no nosso grupo do telegram: https://t.me/naoinviabilizePUBLICIDADE MERCADO LIVRE Para todos os pais que falam que não precisam de nada, mas na verdade estão precisando de tudo: ofertas de até 70% OFF, até 21x sem juros com cartão Mercado Pago e muito mais só no Mercado Livre. Corre pro app fazer comprittas: https://bit.ly/4f7Umc5 Campanha válida até 09/08/2026. Cartão de crédito sujeito à aprovação. Parcelamento elegível a produtos selecionados. Veja condições do Vale Troca em mercadolivre.com.br/l/valetroca. Ver mais condições em Dia dos Pais.QUER OUVIR MAIS HISTÓRIAS? BAIXE NOSSO APLICATIVO EM SUA LOJA APPLE/GOOGLE, CONHEÇA NOSSOS QUADROS EXCLUSIVOS E RECEBA EPISÓDIOS INÉDITOS DE SEGUNDA A SÁBADO: https://naoinviabilize.com.br/assineEnvie a sua história bem detalhada para naoinviabilize@gmail.com, seu anonimato será mantido, todos os nomes, profissões e locais são trocados para preservar a sua identidade.Site: https://naoinviabilize.com.brTranscrição dos episódios: https://naoinviabilize.com.br/episodiosYoutube: https://youtube.com/naoinviabilizeInstagram: https://www.instagram.com/naoinviabilizeTikTok: https://www.tiktok.com/@naoinviabilizeX: https://x.com/naoinviabilizeFacebook: https://facebook.com/naoinviabilizeEdição de áudios: Depois O Leo Corta MultimídiaVinhetas: Pipoca SoundVoz da vinheta: Priscila Armani

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of treating multiple myeloma, focusing on two challenging cases from the community. Joined by experts Marco Davila, MD PhD, from Roswell Park Comprehensive Cancer Center and Krina Patel, MD MSc, from MD Anderson Cancer Center, they discuss the nuances of treatment options for patients experiencing disease relapse post-transplant and disease progression while on maintenance therapy.   Key topics included: The importance of thorough workup and repeat cytogenetics in high-risk multiple myeloma patients The debate between CAR T-cell therapy and bispecific antibodies as treatment options Strategies for managing patients with comorbidities and the role of shared decision-making in treatment planning Insights into the side effects associated with CAR-T and bispecific therapies, including infection risks and neurological symptoms Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/  Join us as we explored the latest advancements in multiple myeloma treatment and the exciting potential for achieving long-term remission and even cure in select patient populations.   Don't forget to like, subscribe, and hit the notification bell for more insightful discussions on oncology! #MultipleMyeloma, #CARTtherapy, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers  

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of diffuse large B-cell lymphoma (DLBCL) for 2026, updating their prior coverage to reflect several recent practice changes.The discussion began with clinical presentation, emphasizing the classic B symptoms—weight loss, night sweats, fatigue, and fever—alongside painless, rapidly enlarging lymphadenopathy. They noted that approximately 30% to 40% of cases present with extranodal involvement (gastrointestinal, central nervous system [CNS], or thyroid) and stressed that an excisional biopsy is required, as fine-needle aspiration cannot preserve the architecture needed for histologic grading.Turning to classification, Drs Armstrong and Tawagi reviewed germinal center vs non-germinal center origin, with non-germinal center disease carrying a worse prognosis. They characterized double-hit lymphoma, triple-hit lymphoma, and double-expressor lymphoma, the last conferring an intermediate prognosis.Regarding workup, they recommended full-body PET scans, laboratory evaluation for tumor lysis syndrome, hepatitis B testing before anti-CD20 therapy, baseline echocardiography before anthracyclines, and lumbar puncture with intrathecal methotrexate in patients at high risk for CNS relapse. They also reviewed updated staging systems.For treatment, they explained that limited-stage disease is now stratified by the stage-modified International Prognostic Index (IPI), guiding abbreviated vs full R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone). In advanced disease, 6 cycles of R-CHOP remains standard, with polatuzumab vedotin-piiq (Polivy) plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisolone) now a category 1 regimen for patients with an IPI of 2 or greater. They also addressed dose-adjusted regimens for double-hit disease, CAR T-cell therapy, and bispecific antibodies in the relapsed/refractory setting, as well as surveillance recommendations, cautioning against routine PET imaging.

The Alan Cox Show

The Alan Cox ShowSee omnystudio.com/listener for privacy information.

More investigation into the strange sets of "cart ruts" we explored in the Phrygian Valley in Turkey. We show more drone footage and photos, look at examples of "cart ruts" from the "Oregon Trail" in Wyoming, as well as actual ruts in mud for comparison. We read more emails with suggestions and ideas and discuss them. Thank you all for your emails and comments! The ruts are a fascinating and enduring mystery.   Support us on Patron or PayPal by going through our support page here: https://www.brothersoftheserpent.com/support   Chapters 00:00 Introduction and episode overview 02:00 Initial observations and setting the scene 04:04 Discussion of recent field visits and findings 06:02 Analysis of the physical characteristics of the ruts 07:59 Theories about water erosion and natural formation 10:04 Possible ancient vehicle or machine origins 11:57 Geological processes like calcification and erosion 13:53 Comparison with Oregon Trail and other historical ruts 15:57 The role of environmental changes and climate shifts 17:59 Discussion of recent scientific insights and hypotheses 19:51 Summary of key points and ongoing questions 02:30 Analysis of Terrain and Material Evidence 04:59 Hypotheses: Watercraft, Sleds, and Carts 10:04 Geological and Material Insights 15:04 Historical Context and Theories 19:51 Practical Considerations and Experiments 25:07 Summary of Key Findings and Open Questions

There is some recent research that's testing out cancer treatments that can utilize the power of our immune systems to attack cancer cells. It's called CAR T-cell therapy and it involves programming immune cells to target and attack cancer in the body. Here to explain more is Dr. Shreya Shukla, a biomedical engineer specializing in this treatment. But first, host Dr. Samantha Yammine will separate hype from fact when it comes to one of the internet's most recent fixations: peptides. Later, Sam digs into a study trying to figure out how pigeons find their way home on a cloudy day. Link to Show Notes HERE Follow Curiosity Weekly on your favorite podcast app to get smarter with Dr. Samantha Yammine — for free! Still curious? Get science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. Terms apply. Hosted on Acast. See acast.com/privacy for more information.

Preparing for postpartum doesn't have to be overwhelming. In this episode, Dr. Morgan shares everything she's putting in her postpartum cart as she prepares for baby number five, including the products she swears by, the items she skips, and why less is often more.From breastfeeding essentials, perineal healing, baby gear, and postpartum supplements to nutrition, mental health, and recovery, this episode is a practical guide for building a postpartum setup that truly supports both mom and baby.Whether you're expecting your first baby or your fifth, you'll walk away knowing what actually deserves a spot on your registry, and what doesn't.00:00 Trailer + Intro02:15 Why You Don't Need Everything07:46 Breastfeeding Essentials09:41 Best Products for Nipple Healing13:44 When to Use a Nipple Shield21:07 Milk Collection & Breast Pads27:24 Active Skin Repair29:47 Electrolytes for Recovery32:23 Milk Supply Support34:29 Nursing Bras35:09 Perineal Healing Essentials39:48 Baby Essentials You Actually Need41:15 Favorite Diapers & Wipes44:35 Baby Clothes & Sleep Setup48:29 Pacifiers & Baby Carriers54:09 Postpartum Comfort & Recovery56:44 Best Postpartum Supplements58:37 Nourishing Herbs & Tonics60:59 Stress & Mental Health Support68:56 Nutrition & Meal Planning74:16 What I Don't BuyResources From This Episode:Get all of the supplies mentioned in this episode here: https://milkmedicine.com/postpartum-cart-links/Healthy As A Mother Podcast | YouTubeHealthy As A Mother Podcast | InstagramHealthy As A Mother Podcast | TikTokHealthy As A Mother Podcast | Merch StoreFind more from Dr. Leah:Dr. Leah Gordon | InstagramDr. Leah Gordon | WebsiteWomanhood Wellness | WebsiteFind more from Dr. Morgan:Dr. Morgan MacDermott | InstagramDr. Morgan MacDermott | WebsiteUse code HEALTHMOTHER and save 10% at Ninni Co.Use code HEALTHYMOTHER and save 10% at EarthleyUse code HEALTHYMOTHER and save 15% at RedmondFor 20% off your first order at Needed, use code HEALTHYMOTHERSave $260 at Lumebox, use code HEALTHYASAMOTHERUse code HAAM and save 10% at Fond

Sam Harris speaks with Siddhartha Mukherjee about the science of cancer. They discuss the updated edition of The Emperor of All Maladies, whether cancer is one disease or many, why prevention is so hard, inflammation and air pollution as carcinogens, the myth that cell phones cause cancer, liquid biopsies and Bayesian reasoning, immunotherapy and CAR T cells, drug pricing, the promise of AI in drug discovery, the state of American medical science, and other topics. If the Making Sense podcast logo in your player is BLACK, you can SUBSCRIBE to gain access to all full-length episodes at samharris.org/subscribe.